Geraldine J Ooi
Overview
Explore the profile of Geraldine J Ooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ooi G, Narasimhan V, Weiser M
Colorectal Dis
. 2023 Dec;
26(1):214-216.
PMID: 38062891
No abstract available.
2.
Ooi G, Narasimhan V, Weiser M
Colorectal Dis
. 2023 Jul;
25(8):1743-1745.
PMID: 37455377
No abstract available.
3.
Montgomery M, Bayliss J, Nie S, De Nardo W, Keenan S, Anari M, et al.
Diabetes
. 2022 Dec;
72(6):715-727.
PMID: 36580496
Nonalcoholic fatty liver disease (NAFLD) and impaired glycemic control are closely linked; however, the pathophysiological mechanisms underpinning this bidirectional relationship remain unresolved. The high secretory capacity of the liver and...
4.
Montgomery M, Bayliss J, Nie S, De Nardo W, Keenan S, Miotto P, et al.
Nat Commun
. 2022 Mar;
13(1):1259.
PMID: 35273160
Non-alcoholic steatohepatitis (NASH) and type 2 diabetes are closely linked, yet the pathophysiological mechanisms underpinning this bidirectional relationship remain unresolved. Using proteomic approaches, we interrogate hepatocyte protein secretion in two...
5.
Mozes F, Lee J, Selvaraj E, Jayaswal A, Trauner M, Boursier J, et al.
Gut
. 2021 May;
71(5):1006-1019.
PMID: 34001645
Objective: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of...
6.
Ooi G, Meikle P, Huynh K, Earnest A, Roberts S, Kemp W, et al.
J Hepatol
. 2021 Apr;
75(3):524-535.
PMID: 33887358
Backgrounds & Aims: Obesity often leads to non-alcoholic fatty liver disease (NAFLD), which can progress from simple steatosis (non-alcoholic fatty liver (NAFL)) to non-alcoholic steatohepatitis (NASH). The accumulation of certain...
7.
Bayliss J, Ooi G, De Nardo W, Shah Y, Montgomery M, McLean C, et al.
Front Endocrinol (Lausanne)
. 2021 Mar;
12:642432.
PMID: 33746906
Clinical Trial Registration: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000875505, identifier ACTRN12615000875505.
8.
Ooi G, Browning A, Hii M, Read M
Ann N Y Acad Sci
. 2020 Aug;
1481(1):224-235.
PMID: 32794237
Obesity is a strong risk factor for Barrett's esophagus (BE), the only proven precursor lesion to esophageal adenocarcinoma (EAC). Bariatric surgery is currently the only reliable treatment that achieves long-term...
9.
Ooi G, Clouston A, Johari Y, Kemp W, Roberts S, Brown W, et al.
Surg Endosc
. 2020 Mar;
35(3):1210-1218.
PMID: 32170564
Background: Liver biopsy remains the gold standard for characterizing and evaluating treatment response in nonalcoholic fatty liver disease (NAFLD). Liver heterogeneity and sampling variability can affect the reliability of results....
10.
Davenport L, Johari Y, Klejn A, Laurie C, Smith A, Ooi G, et al.
Obes Surg
. 2019 Jul;
29(9):2758.
PMID: 31264176
In the original article the name of author Alexandra Klejn was misspelled.